,

Novartis Adds $4 Billion To A Guess


The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines.

  •   1 min read
Novartis Adds $4 Billion To A Guess

Novartis raised its peak sales forecast. Peak sales. A number for a day that has not happened, for a drug that has not hit it.

Kesimpta goes from $6 billion to $8 billion. Scemblix goes from $4 billion to $5 billion. Leqvio goes from $4 billion to $5 billion. Total: $18 billion, up from $14.

Nothing was sold to earn this. A man in London said a bigger number out loud.

CEO Vas Narasimhan credited "in-market commercial performance." Fine. Kesimpta runs at $5.9 billion annualized. Scemblix runs at $2.4 billion. Leqvio runs at $2.0 billion. Those are real sales. The extra billions are vibes in a blazer.

TD Cowen's Steve Scala asked why Leqvio got a raise before the ORION-4 trial read out. Good question. Novartis answered the way every company answers. With another slide.

The stock fell 2.4%. The market looked at $18 billion and shrugged. Why? The company also trimmed its growth outlook to 5% a year through 2031. Kisqali and Cosentyx face cheaper rivals. Entresto is already bleeding to generics.

So Novartis made three drugs bigger on paper to cover for the drugs getting smaller in reality. It is a magic trick where the rabbit is a spreadsheet.

Retail traders will read "raises forecasts" and buy calls. They will hold through the drop. They will call it a dip. They will explain it to their spouse using the word "pipeline."

Citi says the market stays skeptical of growth after 2031. That is a polite way of saying nobody believes a Swiss company's math about a year that is five years away.

I do not care. The chart does not know what Kesimpta is. The chart has never had multiple sclerosis. The chart just goes down 2.4% and waits for you to explain yourself.

Novartis predicted the future, got it wrong by being too optimistic, and still lost money. That is the most relatable thing a drugmaker has ever done for a retail trader.

Photo by on Unsplash

Related Posts

↑

The Noise is free. If Phil's commentary made you laugh or think, he accepts tips. No pressure — the sarcasm was complimentary.

Leave a Tip